Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Evaluation of Artificial Intelligence-enabled Screening for Transthyretin Amyloid Cardiomyopathy (ATTR-CM): TRACE-AI Prospective Study

NCT07398950 is registered in ClinicalTrials.gov with Yale University as lead sponsor.

NCT NCT07398950
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07398950 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Evaluation of Artificial Intelligence-enabled Screening for Transthyretin Amyloid Cardiomyopathy (ATTR-CM): TRACE-AI Prospective Study
Lead sponsor
Yale University
Phase
Observational
Overall status
Enrolling by invitation
Start date
July 31, 2026
Completion date
June 30, 2027
Enrollment
150 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

attr amyloidosis with cardiomyopathy, heart failure